Clarity Pharmaceuticals Ltd.ASX: CU6

Follow-up assessments completed in Phase III AMPLIFY trial

· Issued by Clarity Pharmaceuticals Ltd. via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Clarity Pharmaceuticals Ltd. has announced the completion of follow-up assessments for all participants in its Phase III AMPLIFY trial, which focuses on a diagnostic imaging agent for prostate cancer. Clarity has received Breakthrough Therapy designation from the US FDA for this product, highlighting its potential to significantly improve diagnostic outcomes. Topline data from the AMPLIFY trial is expected to be released in the first half of the following year, which will support applications for FDA approval.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

A S X A N N O U N C E M E N T 19 November 2026 Registrational Phase III AMPLIFY trial: Follow-up assessments completed for all participants Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation...

Clarity Pharmaceuticals Ltd. on 6ix

Story so far

Earlier from Clarity Pharmaceuticals

All Clarity Pharmaceuticals news releases